Combination of bazedoxifene with chemotherapy and SMAC-mimetics for the treatment of colorectal cancer

Rhynelle S. Dmello,Michelle Palmieri,Pathum S. Thilakasiri,Larissa Doughty,Tracy L. Nero,Ashleigh R. Poh,Sarah Q. To,Erinna F. Lee,W. Douglas Fairlie,Lisa Mielke,Michael W. Parker,Ivan K. H. Poon,Eduard Batlle,Matthias Ernst,Ashwini L. Chand

DOI: https://doi.org/10.1038/s41419-024-06631-8

2024-04-10

Cell Death and Disease

Abstract:Excessive STAT3 signalling via gp130, the shared receptor subunit for IL-6 and IL-11, contributes to disease progression and poor survival outcomes in patients with colorectal cancer. Here, we provide evidence that bazedoxifene inhibits tumour growth via direct interaction with the gp130 receptor to suppress IL-6 and IL-11-mediated STAT3 signalling. Additionally, bazedoxifene combined with chemotherapy synergistically reduced cell proliferation and induced apoptosis in patient-derived colon cancer organoids. We elucidated that the primary mechanism of anti-tumour activity conferred by bazedoxifene treatment occurs via pro-apoptotic responses in tumour cells. Co-treatment with bazedoxifene and the SMAC-mimetics, LCL161 or Birinapant, that target the IAP family of proteins, demonstrated increased apoptosis and reduced proliferation in colorectal cancer cells. Our findings provide evidence that bazedoxifene treatment could be combined with SMAC-mimetics and chemotherapy to enhance tumour cell apoptosis in colorectal cancer, where gp130 receptor signalling promotes tumour growth and progression.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to treat colorectal cancer by combining bazedoxifene (BZA), chemotherapy drugs and SMAC analogues (such as LCL161 or Birinapant). Specifically, the research aims to:

1. **Inhibit tumor growth**: By directly binding BZA to the gp130 receptor, inhibit STAT3 signaling mediated by IL - 6 and IL - 11, thereby reducing the proliferation of tumor cells.
2. **Enhance apoptosis**: The study found that BZA can induce apoptosis in tumor cells, and when used in combination with SMAC analogues, can significantly increase the apoptosis rate and reduce cell proliferation.
3. **Improve the effect of chemotherapy**: The study also explored whether BZA can enhance the effect of chemotherapy when combined with standard chemotherapy drugs (such as SN38), especially for the treatment effect on patient - derived colorectal cancer organoids.

### Main research contents

- **Interaction between BZA and gp130**:
- Studies have shown that BZA can directly bind to the D1 domain of the gp130 receptor, block the formation of hexameric complexes in the IL - 6 and IL - 11 signaling pathways, and thus inhibit the activation of STAT3.
- The binding affinity between BZA and gp130 was confirmed by thermal shift analysis and micro - scale thermophoresis (MST).

- **Inhibit the growth of colorectal cancer xenograft tumors**:
- In in - vivo experiments, HT29 cells with gp130 expression knocked down by short - hairpin RNA (shRNA) were used, and it was observed that the tumor growth was significantly slowed down.
- BZA treatment significantly reduced the growth of HT29 cell xenograft tumors, and no toxic reactions were observed.

- **Induce apoptosis**:
- Through flow cytometry and Western blot analysis, it was confirmed that BZA treatment increased the expression of early apoptosis markers, such as cleaved caspase 3 and 8, and the pro - apoptotic proteins of the Bcl - 2 family.
- When BZA was used in combination with SMAC analogues (LCL161 or Birinapant), the apoptosis rate was further enhanced.

- **Synergistic effect with chemotherapy drugs**:
- In the patient - derived colorectal cancer organoid model, when BZA was used in combination with SN38, the anti - proliferative effect was significantly enhanced, especially in organoids sensitive to IL - 6 and IL - 11.

### Conclusion

This study provides evidence that BZA can effectively inhibit the growth of colorectal cancer and induce apoptosis by inhibiting gp130/STAT3 signaling. In addition, when BZA is used in combination with SMAC analogues and chemotherapy drugs, the treatment effect can be significantly enhanced, providing a new strategy for the treatment of colorectal cancer.